TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation

British Journal of Haematology

Volumn 172, Issue 6, 2016, Pages 914-922

  Middeke, Jan M ^a   Herold, Sylvia ^a,b   Rücker Braun, Elke ^a   Berdel, Wolfgang E ^c   Stelljes, Matthias ^c   Kaufmann, Martin ^d   Schäfer Eckart, Kerstin ^e   Baldus, Claudia D ^f   Stuhlmann, Reingard ^g   Ho, Anthony D ^h   Einsele, Hermann ⁱ   Rösler, Wolf ^j   Serve, Hubert ^k   Hänel, Mathias ^l   Sohlbach, Kristina ^m   Klesse, Christian ⁿ   Mohr, Brigitte ^a   Heidenreich, Falk ^a   Stölzel, Friedrich ^a   Röllig, Christoph ^a   Platzbecker, Uwe ^a   Ehninger, Gerhard ^a   Bornhäuser, Martin ^a   Thiede, Christian ^a,b   Schetelig, Johannes ^a,n   more..

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d ROBERT BOSCH HOSPITAL   (Germany)

^e KLINIKUM NÜRNBERG   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g DEPARTMENT OF CARDIOLOGY   (Germany)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^j UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^k UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^l KLINIKUM CHEMNITZ   (Germany)

^m UNIVERSITY HOSPITAL MARBURG   (Germany)

ⁿ DKMS German Bone Marrow Donor Centre   (Germany)

more..

Author keywords

Acute myeloid leukaemia; Allogeneic transplantation; TP53 mutation

Indexed keywords

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CHROMOSOME DELETION; CONTROLLED STUDY; CYTOGENETICS; DNA POLYMORPHISM; EVENT FREE SURVIVAL; FOLLOW UP; G1 PHASE CELL CYCLE CHECKPOINT; GENE FUNCTION; GENE MUTATION; GENE SEQUENCE; HAZARD RATIO; HIGH RISK PATIENT; HUMAN; HUMAN CELL; KARYOTYPE; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MONOSOMY; MUTATIONAL ANALYSIS; MYELOABLATIVE CONDITIONING; NEXT GENERATION SEQUENCING; OVERALL SURVIVAL; P72R GENE; PRIORITY JOURNAL; PROBABILITY; PROMOTER REGION; RANDOMIZED CONTROLLED TRIAL; REDUCED INTENSITY CONDITIONING; REFRACTORY DISEASE; SINGLE NUCLEOTIDE POLYMORPHISM; TP53 GENE; TUMOR SUPPRESSOR GENE; ADOLESCENT; CHROMOSOME ABERRATION; DNA MUTATIONAL ANALYSIS; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA, MYELOID, ACUTE; META ANALYSIS; MIDDLE AGED; MUTATION; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

DNA;

ADOLESCENT; ADULT; AGED; CHROMOSOME ABERRATIONS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; GENES, P53; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84960091270     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13912     Document Type: Article

References (26)

1. Bally, C., Adès, L., Renneville, A., Sebert, M., Eclache, V., Preudhomme, C., Mozziconacci, M.-J., de The, H., Lehmann-Che, J. & Fenaux, P. (2015) Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine. Leukemia Research, 38, 751-755.
2. Bejar, R., Lord, A., Stevenson, K., Bar-Natan, M., Pérez-Ladaga, A., Zaneveld, J., Wang, H., Caughey, B., Stojanov, P., Getz, G., Garcia-Manero, G., Kantarjian, H., Chen, R., Stone, R.M., Neuberg, D., Steensma, D.P. & Ebert, B.L. (2014) TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood, 124, 2705-2712.
3. Döhner, H., Estey, E.H., Amadori, S., Appelbaum, F.R., Büchner, T., Burnett, A.K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., Lo-Coco, F., Naoe, T., Niederwieser, D., Ossenkoppele, G.J., Sanz, M. A., Sierra, J., Tallman, M.S., Löwenberg, B. & Bloomfield, C.D. (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood, 115, 453-474.
4. Dumont, P., Leu, J.I.-J., Della Pietra, A.C., George, D.L. & Murphy, M. (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nature Genetics, 33, 357-365.
5. Dunna, N.R., Vure, S., Sailaja, K., Surekha, D., Raghunadharao, D., Rajappa, S. & Vishnupriya, S. (2012) TP53 Codon 72 Polymorphism and Risk of acute leukemia. Asian Pacific Journal of Cancer Prevention, 13, 347-350.
6. Ellis, N.A., Huo, D., Yildiz, O., Worrillow, L.J., Banerjee, M., Le Beau, M.M., Larson, R.A., Allan, J.M. & Onel, K. (2008) MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood, 112, 741-749. Available at: http://www.bloodjournal.org/content/112/3/741.abstract.
7. Grossmann, V., Schnittger, S., Kohlmann, A., Eder, C., Roller, A., Dicker, F., Schmid, C., Wendtner, C.M., Staib, P., Serve, H., Kreuzer, K.A., Kern, W., Haferlach, T. & Haferlach, C. (2012) A novel hierarchical prognostic model of AML solely based on molecular mutations. Blood, 120, 2963-2972.
8. Haferlach, C., Dicker, F., Herholz, H., Schnittger, S., Kern, W. & Haferlach, T. (2008) Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K, 22, 1539-1541.
9. Kohlmann, A., Martinelli, G., Alikian, M., Artusi, V., Auber, B., Belickova, M., Bronzini, I., Cazzaniga, G., Chiaretti, S., Ernst, T., Fuellgrabe, M., Gabriel, C., Hernandez, J., Jansen, J.H., Iacobucci, I., Lion, T., Lode, L., Martinez-Lopez, J., Mills, K.I., Mossner, M., Polakova, K.M., Porret, N.A., Pospisilova, S., Preudhomme, C., Sayitoglu, M., Soverini, S., Spinelli, O., Thiede, C., Vandenberghe, P., Yeoh, J.E., Hochhaus, A. & Haferlach, T. (2013) The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: deep-sequencing analyses of hematological malignancies performed In 8, 867 cases by an international network involving 27 laboratories. Blood, 122, 743.
10. Middeke, J.M., Fang, M., Cornelissen, J.J., Mohr, B., Appelbaum, F.R., Stadler, M., Sanz, J., Baurmann, H., Bug, G., Schäfer-Eckart, K., Hegenbart, U., Bochtler, T., Röllig, C., Stölzel, F., Walter, R.B., Ehninger, G., Bornhäuser, M., Löwenberg, B. & Schetelig, J. (2014) Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Blood, 123, 2960-2967.
11. Mohr, B., Schetelig, J., Schäfer-Eckart, K., Schmitz, N., Hänel, M., Rösler, W., Frickhofen, N., Link, H., Neubauer, A., Schuler, U., Platzbecker, U., Middeke, J.M., Ehninger, G., Bornhäuser, M., Schaich, M. & Stölzel, F. (2013) Impact of allogeneic haematopoietic stem cell transplantation in patients with abnl(17p) acute myeloid leukaemia. British Journal of Haematology, 161, 237-244.
12. Müller-Thomas, C., Rudelius, M., Rondak, I.-C., Haferlach, T., Schanz, J., Huberle, C., Schmidt, B., Blaser, R., Kremer, M., Peschel, C., Germing, U., Platzbecker, U. & Götze, K. (2014) Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia. Haematologica, 2, 179-181.
13. Pan, R., Hogdal, L.J., Benito, J.M., Bucci, D., Han, L., Borthakur, G., Cortes, J., DeAngelo, D.J., Debose, L., Mu, H., Döhner, H., Gaidzik, V.I., Galinsky, I., Golfman, L.S., Haferlach, T., Harutyunyan, K.G., Hu, J., Leverson, J.D., Marcucci, G., Müschen, M., Newman, R., Park, E., Ruvolo, P.P., Ruvolo, V., Ryan, J., Schindela, S., Zweidler-McKay, P., Stone, R.M., Kantarjian, H., Andreeff, M., Konopleva, M. & Letai, A.G. (2014) Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid Leukemia. Cancer Discovery, 4, 362-675.
14. Platzbecker, U., Braulke, F., Kündgen, A, Götze, K., Bug, G., Schönefeldt, C., Shirneshan, K., Röllig, C., Bornhäuser, M., Naumann, R., Neesen, J., Giagounidis, A, Hofmann, W.-K., Ehninger, G., Germing, U., Haase, D. & Wermke, M. (2013) Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study. Leukemia, 27, 1403-1407.
15. Röllig, C., Thiede, C., Gramatzki, M., Aulitzky, W., Bodenstein, H., Bornhäuser, M., Platzbecker, U., Stuhlmann, R., Schuler, U., Soucek, S., Kramer, M., Mohr, B., Oelschlaegel, U., Stölzel, F., von Bonin, M., Wermke, M., Wandt, H., Ehninger, G. & Schaich, M. (2010) A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. Blood, 116, 971-978.
16. Royds, J.A. & Iacopetta, B. (2006) p53 and disease: when the guardian angel fails. Cell Death and Differentiation, 13, 1017-1026.
17. Rücker, F.G., Schlenk, R.F., Bullinger, L., Kayser, S., Teleanu, V., Kett, H., Habdank, M., Kugler, C.M., Holzmann, K., Gaidzik, V.I., Paschka, P., Held, G., Von Lilienfeld-Toal, M., Lübbert, M., Fröhling, S., Zenz, T., Krauter, J., Schlegelberger, B., Ganser, A., Lichter, P., Döhner, K. & Döhner, H. (2012) TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood, 119, 2114-2121.
18. Schaich, M., Röllig, C., Soucek, S., Kramer, M., Thiede, C., Mohr, B., Oelschlaegel, U., Schmitz, N., Stuhlmann, R., Wandt, H., Schäfer-Eckart, K., Aulitzky, W., Kaufmann, M., Bodenstein, H., Tischler, J., Ho, A., Krämer, A., Bornhäuser, M., Schetelig, J. & Ehninger, G. (2011) Cytarabine dose of 36 g/m2 compared with 12 g/m2 within first consolidation in acute myeloid leukemia: Results of patients enrolled onto the prospective randomized AML96 study. Journal of Clinical Oncology, 29, 2696-2702.
19. Schaich, M., Parmentier, S., Kramer, M., Illmer, T., Stölzel, F., Röllig, C., Thiede, C., Hänel, M., Schäfer-Eckart, K., Aulitzky, W., Einsele, H., Ho, A.D., Serve, H., Berdel, W.E., Mayer, J., Schmitz, N., Krause, S.W., Neubauer, A., Baldus, C.D., Schetelig, J., Bornhäuser, M. & Ehninger, G. (2013) High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 31, 2094-2102.
20. Schulz, E., Valentin, A., Ulz, P., Beham-Schmid, C., Lind, K., Rupp, V., Lackner, H., Wolfler, A., Zebisch, A., Olipitz, W., Geigl, J., Berghold, A., Speicher, M.R. & Sill, H. (2012) Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms. Journal of Medical Genetics, 49, 422-428.
21. Schulz, E., Kashofer, K., Heitzer, E., Mhatre, K.N., Speicher, M.R., Hoefler, G. & Sill, H. (2014) Preexisting TP53 mutation in therapy-related acute myeloid leukemia. Annals of Hematology, 94, 527-529.
22. Seifert, H., Mohr, B., Thiede, C., Oelschlägel, U., Schäkel, U., Illmer, T., Soucek, S., Ehninger, G. & Schaich, M. (2009) The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia. Leukemia, 23, 656-663.
23. Soussi, T. & Béroud, C. (2001) Assessing TP53 status in human tumours to evaluate clinical outcome. Nature Reviews. Cancer, 1, 233-240.
24. Weng, Y., Lu, L., Yuan, G., Guo, J., Zhang, Z., Xie, X., Chen, G. & Zhang, J. (2012) p53 codon 72 polymorphism and Hematological Cancer Risk: an Update Meta-Analysis. PLoS ONE, 7, e45820.
25. Whibley, C., Pharoah, P.D.P. & Hollstein, M. (2009) P53 Polymorphisms: cancer implications. Nature Reviews. Cancer, 9, 95-107.
26. Wong, T.N., Ramsingh, G., Young, A.L., Miller, C.A., Touma, W., Welch, J.S., Lamprecht, T.L., Shen, D., Hundal, J., Fulton, R.S., Heath, S., Baty, J.D., Klco, J.M., Ding, L., Mardis, E.R., Westervelt, P., DiPersio, J.F., Walter, M.J., Graubert, T.A., Ley, T.J., Druley, T.E., Link, D.C. & Wilson, R.K. (2015) Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature, 518, 552-555.